Powell đã tham dự sự kiện của Ban Tài chính Quốc tế của Fed: tưởng nhớ Fischer, nhắc lại tầm quan trọng của nghiên cứu kinh tế toàn cầu và không thảo luận về triển vọng chính sách

SAB Biotherapeutics

company

About

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$14M
Industries
Biotechnology,Clinical Trials,Therapeutics
Founded date
Jun 1, 2014
Number Of Employee
51 - 100
Operating Status
Active

A biopharmaceutical development company leading the science and manufacturing of antibody therapeutics. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large-scale platform to create immunoglobulins. This natural production platform holds the potential for treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$15.42M
SAB Biotherapeutics has raised a total of $15.42M in funding over 2 rounds. Their latest funding was raised on Jul 17, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jul 17, 2020 Series B $14M 1 Detail
Sep 7, 2016 Grant $1.42M 1 National Institutes of Health Detail

Investors

Number of Lead Investors
Number of Investors
1
2
SAB Biotherapeutics is funded by 2 investors. National Institutes of Health and Merck are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Yes Grant
Merck Series B